←
Vadim Demichev1,572 posts
Vadim Demichev avatar

Vadim Demichev

@DemichevLab

Founder of Aptila Biotech. Proteomics technologies and applications, DIA-NN author.

◷ Joined November 2018▧ 113 Photos and videos
Vadim Demichev avatar
Vadim Demichev@DemichevLab·Apr 13

We are delighted to present DIA-NN 2.5. Redefining LC-MS proteomics with up to 70% more proteins identified and powerful capabilities for statistics, visualisation and biological interpretation.

Post attachment
Vadim Demichev avatar
Vadim Demichev@DemichevLab·23h

An incredible work and a massive dataset by Tiannan Guo @guomics and colleagues, mapping region-resolved proteome, phosphoproteome, acetylome and ubiquitinome of the ageing brain. The authors uncover major differences in the observed ageing signature across brain regions, as well as compare WT and telomerase-deficient mice. mcponline.org/article/S1535-…

Vadim Demichev avatar
Vadim Demichev@DemichevLab·Oct 29

It is remarkable how we are able to improve the performance and capabilities of our DIA-NN proteomics software at an ever-increasing pace. Sneak peek at the upcoming DIA-NN 2.8 Enterprise: - A major increase in identification numbers, in particular with InfinDIA: 25%+ on some datasets compared to 2.7. - Support for three additional technologies beyond ordinary DIA and DDA. Guess which ones? Back in the days of DIA-NN 1.8.1, released in early 2022, I genuinely thought we were close to the ceiling of how deeply we could see into the data. Turns out, that could not have been further from the truth. We have achieved massive gains in proteomic depth over the past year, and the pace is accelerating. Each advance is a step not only towards properly utilising the full potential of the very expensive mass spectrometry instrumentation, but also towards our ability to extract more knowledge from existing data. Automated reanalysis of ProteomeXchange repositories at scale - who knows what we might find there?

Vadim Demichev avatar
Vadim Demichev@DemichevLab·Oct 20

Read our application note exploring how DIA-NN 2.7 Enterprise can power host cell protein (HCP) analysis for biotherapeutics. Link in comments below.

Post attachment
Matthias Mann Lab avatar
⟳ Vadim Demichev retweeted
Matthias Mann Lab@labs_mann·Oct 9

Can MS-based proteomics see what histology can’t? We profiled 83 rare paediatric adrenocortical tumours from archival FFPE tissue & found 4 proteome-defined states that predict survival better. Now in @eBioMedicine, led by Rainer Claus & Andreas Metousis. doi.org/10.1016/j.ebiom.2026…

Matthias Mann Lab avatar
⟳ Vadim Demichev retweeted
Matthias Mann Lab@labs_mann·Oct 6

SPARCS: Deep Visual Proteomics-style laser microdissection meets genome-wide CRISPR screening. Find genes behind how cells look, isolate them, profile them by mass spec. Now in @CellCellPress! Tweetorial from @niklas_a_s follows🧵 doi.org/10.1016/j.cell.2026.…

Out now in @CellCellPress: ✨SPARCS✨, a platform for discovering the genes behind complex cellular phenotypes. SPARCS combines Al-powered image analysis with automated laser microdissection to precisely isolate cells from large mutant libraries. Paper and highlights👇(1/9)

Vadim Demichev avatar
Vadim Demichev@DemichevLab·Sep 29

Aptila Biotech today announces a collaboration with IonOpticks, a global leader in high-performance chromatography solutions. Through this partnership, Aptila will support IonOpticks in deploying DIA-NN Enterprise across its chromatography systems and mass spectrometry method development, while IonOpticks will supply Aptila with state-of-the-art mass spectrometry data to help further optimise DIA-NN.

Post attachment
Matthias Mann Lab avatar
⟳ Vadim Demichev retweeted
Matthias Mann Lab@labs_mann·Sep 28

New preprint: with ADAPT-MS, discovery plasma proteomics becomes a diagnostic tool for ovarian cancer. We separate benign from malignant adnexal masses and generalize to 5 validation cohorts. Collaboration with @ErnstLengyel @OvCa_UChicago. medrxiv.org/content/10.64898…

Vadim Demichev avatar
Vadim Demichev@DemichevLab·Sep 28

Means everyone can now get the full package for proteomics from Thermo: the MS + Evosep + DIA-NN!

Today, Evosep announced a new reseller agreement with Thermo Fisher Scientific, through which Thermo Fisher Scientific will offer the Evosep Eno separation platform as part of its mass spectrometry solutions portfolio. Read the press release here: evosep.com/wp-content/upload…

Post attachment
Vadim Demichev avatar
Vadim Demichev@DemichevLab·Sep 16

We have released DIA-NN 2.7. Performance improvements (more proteins) and GUI improvements. In particular, added a data completeness filter for pathway analysis. Further feedback on how to improve statistics and visualisation in DIA-NN is very welcome!

Post attachment
Matthias Mann Lab avatar
⟳ Vadim Demichev retweeted
Matthias Mann Lab@labs_mann·Aug 27

Same single cell, two modalities—both at depth. We digest protein first, run Smart-seq3xpress + C18 (Evotip) separation: peptides captured, cDNA in flowthrough. In HeLa & stem cells, proteome tracks cell state; RNA variance flags transitioning cells. biorxiv.org/content/10.64898…